

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7653781

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the EXECUTION DATE FOR THE ASSIGNOR previously recorded on Reel 052923 Frame 0313. Assignor(s) hereby confirms the EXECUTION DATE IS 12/14/2017.
CONVEYING PARTY DATA	
Name	Execution Date
HAGER BIOSCIENCES	12/14/2017
RECEIVING PARTY DATA	
Name:	AGENEBIO, INC.
Street Address:	1340 SMITH AVENUE
Internal Address:	SUITE 200
City:	BALTIMORE
State/Country:	MARYLAND
Postal Code:	21209
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16471237
Application Number:	62436272
CORRESPONDENCE DATA	
Fax Number:	(646)219-6229
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	carolina.rodriquez@hglaw.com
Correspondent Name:	HALEY GUILIANO LLP
Address Line 1:	75 BROAD STREET
Address Line 2:	SUITE 1000
Address Line 4:	NEW YORK, NEW YORK 10004
ATTORNEY DOCKET NUMBER:	107042-0025-301, 001
NAME OF SUBMITTER:	CAROLINA RODRIGUEZ
SIGNATURE:	/Carolina Rodriguez/
DATE SIGNED:	11/18/2022
Total Attachments: 11	
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page1.tif	
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page2.tif	

source=107042-0025-301-Corrective Assignment (Hager-Agene)#page3.tif
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page4.tif
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page5.tif
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page6.tif
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page7.tif
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page8.tif
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page9.tif
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page10.tif
source=107042-0025-301-Corrective Assignment (Hager-Agene)#page11.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6150907

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	HAGER BIOSCIENCES	06/12/2010
RECEIVING PARTY DATA		
Name:	AGENEBIO, INC.	
Street Address:	1340 SMITH AVENUE, SUITE 200	
City:	BALTIMORE	
State/Country:	MARYLAND	
Postal Code:	21209	
PROPERTY NUMBERS Total: 2		
Property Type	Number	
Application Number:	16471237	
Application Number:	62436272	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	MARIA.MARLEY@HGLAW.COM	
Correspondent Name:	HALEY GUILIANO LLP	
Address Line 1:	75 BROAD STREET, SUITE 1000	
Address Line 4:	NEW YORK, NEW YORK 10004	
ATTORNEY DOCKET NUMBER:	107042-0025-301, 001	
NAME OF SUBMITTER:	MARIA E. MARLEY	
SIGNATURE:	/MARIA E. MARLEY/	
DATE SIGNED:	06/12/2020	
Total Attachments: 10		
source=107042-0025-301-Hager-Agene#page1.tif		
source=107042-0025-301-Hager-Agene#page2.tif		
source=107042-0025-301-Hager-Agene#page3.tif		
source=107042-0025-301-Hager-Agene#page4.tif		
source=107042-0025-301-Hager-Agene#page5.tif		
source=107042-0025-301-Hager-Agene#page6.tif		

ASSIGNMENT

We, HAGER BIOSCIENCES, residing at 116 Research Dr., Suite 265, Bethlehem, PA 18015, USA, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to AGENE BIO, INC., a corporation organized and existing under the laws of the State of Delaware and having an office and a place of business at 1101 E. 33rd Street, Suite C310, Baltimore, MD 21218, USA, its successors and assigns (1) the entire right, title and interest in the United States and in all countries throughout the world in and to any and all our inventions and discoveries disclosed in the following applications:

- (i) United States Provisional Application No. 62/436,272, filed December 19, 2016, and entitled "BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT";
- (ii) An International Patent Application that claims priority to application (i) above, filed/to be filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US) on December 20, 2017 * and assigned serial number PCT/IB2017/001762 * entitled "BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT", designating all PCT member states, including Albania (AL), Algeria (DZ), Angola (AO), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Bahrain (BH), Barbados (BB), Belarus (BY), Belgium (BE), Belize (BZ), Benin (BJ), Bosnia and Herzegovina (BA), Botswana (BW), Brazil (BR), Bulgaria (BG), Brunei Darussalam (BN), Burkina Faso (BF), Cambodia (KH), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), Chile (CL), China (CN), Colombia (CO), Comoros (KM), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czechia (CZ),

* We hereby authorize AGENE BIO, INC. to insert in this instrument the deposit date of the respective application when the date is known and the serial number of said application when AGENE BIO, INC. is officially notified thereof.

Democratic People's Republic of Korea (KP), Denmark (DK), Djibouti (DJ),
Dominica (DM), Dominican Republic (DO), Ecuador (EC), Egypt (EG), El
Salvador (SV), Equatorial Guinea (GQ), Estonia (EE), Finland (FI), France
(FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana
(GH), Greece (GR), Grenada (GD), Guatemala (GT), Guinea (GN), Guinea
Bissau (GW), Honduras (HN), Hungary (HU), Iceland (IS), India (IN),
Indonesia (ID), Ireland (IE), Islamic Republic of Iran (IR), Israel (IL), Italy
(IT), Japan (JP), Jordan (JO), Kazakhstan (KZ), Kenya (KE), Kuwait (KW),
Kyrgyzstan (KG), Lao People's Democratic Republic (LA), Latvia (LV),
Lesotho (LS), Liberia (LR), Libya (LY), Liechtenstein (LI), Lithuania (LT),
Luxembourg (LU), Madagascar (MG), the former Yugoslav Republic of
Macedonia (MK), Malawi (MW), Malaysia (MY), Mali (ML), Malta (MT)
Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Montenegro
(ME), Morocco (MA), Mozambique (MZ), Namibia (NA), Netherlands (NL),
New Zealand (NZ), Nicaragua (NI), Niger (NE), Nigeria (NG), Norway (NO),
Oman (OM), Panama (PA), Papua New Guinea (PG), Peru (PE),
Philippines (PH), Poland (PL), Portugal (PT), Qatar (QA), Republic of Korea
(KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU),
Rwanda (RW), Saint Lucia (LC), Saint Kitts and Nevis (KN), Saint Vincent
and the Grenadines (VC), San Marino (SM), São Tomé and Príncipe (ST),
Saudi Arabia (SA), Senegal (SN), Serbia (RS), Seychelles (SC), Sierra Leone
(SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain
(ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland
(CH), Syrian Arab Republic (SY), Tajikistan (TJ), United Republic of
Tanzania (TZ), Togo (TG), Thailand (TH), Trinidad and Tobago (TT), Tunisia
(TN), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United
Arab Emirates (AE), United Kingdom (GB), United States of America (US),
Uzbekistan (UZ), Viet Nam (VN), Zambia (ZM) and Zimbabwe (ZW);

including any applications and patents claiming priority therefrom, and any renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of AGENE BIO, INC., its designee, or in our names at AGENE BIO, INC. or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent that claims priority therefrom in the United States or in any other country of the world and any renewals, revivals, reissues, reexaminations, supplementary protection certificates, and

extensions of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to AGENEBIO, INC. as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of AGENEBIO, INC. to execute and to deliver to AGENEBIO, INC. any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.


We further agree at any time to execute and to deliver upon request of AGENEBIO, INC. such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of AGENEBIO, INC. under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.


ASSIGNOR:


HAGER BIOSCIENCES

By: 
Name: Belew Mekonnen
Title: President & CEO

On this 14th day of December, 2017, Belew Mekonnen
personally appeared before me, a Notary Public in and for the state of Pennsylvania
 , and duly acknowledged the executed Assignment on behalf of the Assignor.





Notary Public





ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of
AGENE BIO, INC.

By: 
Name: Gerald W. McLaughlin
Title: President & CEO

On this 18th day of December, 2017, Gerald W. McLaughlin personally
appeared before me, a Notary Public in and for the state of Pa, and
duly acknowledged the executed Assignment on behalf of the Assignee.


Notary Public



ASSIGNMENT

We, HAGER BIOSCIENCES, residing at 116 Research Dr., Suite 265, Bethlehem, PA 18015, USA, for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to and do hereby assign, sell and transfer to AGENEBIO, INC., a corporation organized and existing under the laws of the State of Delaware and having an office and a place of business at 1340 Smith Avenue, Suite 200, Baltimore, MD 21209, USA, its successors and assigns (1) the entire right, title and interest in the United States and in all countries throughout the world in and to any and all our inventions and discoveries disclosed in the following applications:

- (i) United States Patent Application No. 16/471,237, filed June 19, 2019, and entitled "BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT";
- (ii) United States Provisional Application No. 62/436,272, filed December 19, 2016, and entitled "BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT";
- (iii) An International Patent Application that claims priority to application (i) above, filed/to be filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US) on December 20, 2017 and assigned serial number PCT/IB2017/001762, entitled "BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT", designating all PCT member states, including Albania (AL), Algeria (DZ), Angola (AO), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Bahrain (BH), Barbados (BB), Belarus (BY), Belgium (BE), Belize (BZ), Benin (BJ), Bosnia and Herzegovina (BA), Botswana (BW), Brazil (BR), Bulgaria (BG), Brunei Darussalam (BN), Burkina Faso (BF), Cambodia (KH), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), Chile (CL), China (CN), Colombia (CO), Comoros (KM), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czechia (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Djibouti (DJ), Dominica (DM), Dominican Republic (DO), Ecuador (EC), Egypt (EG), El

Salvador (SV), Equatorial Guinea (GQ), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guatemala (GT), Guinea (GN), Guinea Bissau (GW), Honduras (HN), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Islamic Republic of Iran (IR), Israel (IL), Italy (IT), Japan (JP), Jordan (JO), Kazakhstan (KZ), Kenya (KE), Kuwait (KW), Kyrgyzstan (KG), Lao People's Democratic Republic (LA), Latvia (LV), Lesotho (LS), Liberia (LR), Libya (LY), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), the former Yugoslav Republic of Macedonia (MK), Malawi (MW), Malaysia (MY), Mali (ML), Malta (MT), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Montenegro (ME), Morocco (MA), Mozambique (MZ), Namibia (NA), Netherlands (NL), New Zealand (NZ), Nicaragua (NI), Niger (NE), Nigeria (NG), Norway (NO), Oman (OM), Panama (PA), Papua New Guinea (PG), Peru (PE), Philippines (PH), Poland (PL), Portugal (PT), Qatar (QA), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Rwanda (RW), Saint Lucia (LC), Saint Kitts and Nevis (KN), Saint Vincent and the Grenadines (VC), San Marino (SM), São Tomé and Príncipe (ST), Saudi Arabia (SA), Senegal (SN), Serbia (RS), Seychelles (SC), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Syrian Arab Republic (SY), Tajikistan (TJ), United Republic of Tanzania (TZ), Togo (TG), Thailand (TH), Trinidad and Tobago (TT), Tunisia (TN), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Zambia (ZM) and Zimbabwe (ZW);

including any applications and patents claiming priority therefrom, and any renewals, revivals, reissues, reexaminations, extensions, supplementary protection certificates, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of AGENEBIO, INC., its designee, or in our names at AGENEBIO, INC. or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent that claims priority therefrom in the United States or in any other country of the world and any renewals, revivals, reissues, reexaminations, supplementary protection certificates, and extensions of the same; and (4) the entire right, title and interest in all Convention and

Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to AGENEBIO, INC. as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of AGENEBIO, INC. to execute and to deliver to AGENEBIO, INC. any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request of AGENEBIO, INC. such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of AGENEBIO, INC. under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNOR:

HAGER BIOSCIENCES

By: Bel Mhl
Name: Belew Mekonnen
Title: President & CEO

On this 19th day of February, 2020, Belew Mekonnen
personally appeared before me, a Notary Public in and for the state of Pennsylvania
_____, and duly acknowledged the executed Assignment on behalf of the Assignor.

Julie Ann Riedy
Notary Public

COMMONWEALTH OF PENNSYLVANIA
NOTARIAL SEAL
Julie Ann Riedy, Notary Public
City of Bethlehem, Northampton County
My Commission Expires Dec. 18, 2020
MEMBER, PENNSYLVANIA ASSOCIATION OF NOTARIES

ACKNOWLEDGEMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed Assignment on behalf of
AGENEBIO, INC.

By: Michela Gallagher
Name: Michela Gallagher
Title: President & CEO

On this 12 day of June, 2020, Michela Gallagher personally
appeared before me, a Notary Public in and for the state of _____, and
duly acknowledged the executed Assignment on behalf of the Assignee.

Notary Public